🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/07/2004 | 10,04 | 10,20 | 9,83 | 10,06 | +0,30% | 3,69% | 636.400 |
| 19/07/2004 | 9,80 | 10,04 | 9,73 | 10,03 | +2,14% | 3,16% | 821.500 |
| 16/07/2004 | 10,53 | 10,65 | 9,81 | 9,82 | -0,81% | 7,98% | 1.060.400 |
| 15/07/2004 | 10,00 | 10,17 | 9,86 | 9,90 | -1,59% | 3,10% | 279.300 |
| 14/07/2004 | 10,00 | 10,20 | 9,80 | 10,06 | -0,30% | 4,00% | 622.300 |
| 13/07/2004 | 10,20 | 10,33 | 10,04 | 10,09 | -0,69% | 2,84% | 282.700 |
| 12/07/2004 | 10,09 | 10,24 | 9,77 | 10,16 | +1,40% | 4,66% | 449.100 |
| 09/07/2004 | 10,14 | 10,27 | 9,91 | 10,02 | -0,20% | 3,55% | 333.400 |
| 08/07/2004 | 10,65 | 10,70 | 10,00 | 10,04 | -6,52% | 6,57% | 701.800 |
| 07/07/2004 | 10,39 | 10,74 | 10,34 | 10,74 | +3,87% | 3,85% | 675.500 |
| 06/07/2004 | 10,58 | 10,76 | 10,31 | 10,34 | -2,36% | 4,25% | 506.300 |
| 02/07/2004 | 10,79 | 10,85 | 10,54 | 10,59 | -1,40% | 2,87% | 518.700 |
| 01/07/2004 | 10,77 | 11,19 | 10,65 | 10,74 | -0,92% | 5,01% | 786.000 |
| 30/06/2004 | 10,79 | 10,99 | 10,72 | 10,84 | +0,93% | 2,50% | 629.600 |
| 29/06/2004 | 10,43 | 10,98 | 10,34 | 10,74 | +2,29% | 6,14% | 768.400 |
| 28/06/2004 | 10,94 | 10,94 | 10,32 | 10,50 | -0,76% | 5,67% | 439.000 |
| 25/06/2004 | 10,67 | 10,97 | 10,41 | 10,58 | -1,31% | 5,25% | 1.294.200 |
| 24/06/2004 | 10,44 | 10,86 | 10,41 | 10,72 | +2,19% | 4,31% | 969.700 |
| 23/06/2004 | 10,57 | 10,57 | 10,15 | 10,49 | +3,35% | 3,97% | 1.482.600 |
| 22/06/2004 | 10,45 | 10,66 | 10,02 | 10,15 | +4,32% | 6,12% | 1.881.300 |
| 21/06/2004 | 9,98 | 10,04 | 9,73 | 9,73 | -2,01% | 3,11% | 627.900 |
| 18/06/2004 | 9,70 | 10,33 | 9,56 | 9,93 | +3,98% | 7,94% | 1.749.400 |
| 17/06/2004 | 9,71 | 9,71 | 9,46 | 9,55 | -1,04% | 2,57% | 448.900 |
| 16/06/2004 | 9,55 | 9,75 | 9,47 | 9,65 | +0,00% | 2,93% | 481.700 |
| 15/06/2004 | 9,59 | 9,66 | 9,40 | 9,65 | +1,79% | 2,71% | 786.600 |
| 14/06/2004 | 9,40 | 9,62 | 9,20 | 9,48 | +2,49% | 4,47% | 984.300 |
| 10/06/2004 | 9,05 | 9,25 | 9,01 | 9,25 | +3,01% | 2,65% | 1.670.000 |
| 09/06/2004 | 9,13 | 9,34 | 8,87 | 8,98 | -2,60% | 5,15% | 690.600 |
| 08/06/2004 | 9,20 | 9,48 | 9,10 | 9,22 | +0,33% | 4,13% | 676.800 |
| 07/06/2004 | 9,25 | 9,30 | 9,00 | 9,19 | -0,65% | 3,24% | 919.900 |